CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

Trial Details

NCT ID

NCT07322094

Phase

PHASE1 / PHASE2

Sponsor

TORL Biotherapeutics, LLC

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

• TORL-1-23 and paclitaxel
• TORL-1-23 and carboplatin
• TORL-1-23, paclitaxel, and carboplatin

Locations (sample)

• Fullerton, California, United States|33.87029,-117.92534
• Irvine, California, United States|33.66946,-117.82311
• Los Angeles, California, United States|34.05223,-118.24368
• Los Angeles, California, United States|34.05223,-118.24368
• Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
• Histologically or cytologically confirmed diagnosis of epithelial ovarian, primary peritoneal or fallopian tubes cancer
• FIGO Stage III or IV
• Positive for claudin 6 (CLDN6) expression

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.